Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGO 2021 | Durvalumab and oleclumab in patients with relapsed ovarian cancer

Mansoor Mirza • 24 Oct 2021
ESGO 2021
Gynecological Cancer Ovarian Cancer Antibodies Durvalumab Oleclumab

Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses the findings of a Phase II NSGO-OV-UMB1/ENGOT-OV30 study evaluating durvalumab and oleclumab, a monoclonal antibody against CD73, in patients with relapsed ovarian cancer. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

More from Mansoor Mirza

2:11
Long-term benefit from 1L maintenance PARP inhibitors in ovarian cancer
Mansoor Mirza • 29 Sep 2022
4:15
Optimal management of recurrent low grade endometrial cancer
Mansoor Mirza • 29 Sep 2022
2:20
ENGOT-EN1: carboplatin plus paclitaxel plus nintedanib for endometrial cancer
Mansoor Mirza • 24 Oct 2021
8:20
Immune checkpoint inhibitors for endometrial and cervical cancer
Mansoor Mirza • 24 Oct 2021

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals